{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:03:47Z","timestamp":1791140627380,"version":"4.1.0"},"reference-count":9,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,7,7]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Drug-induced lung injury represents a heterogeneous group of adverse reactions, with an increasing number of implicated medications each year. We report a case of pneumonitis in a woman recently commenced on upadacitinib for ulcerative colitis. She presented with dyspnoea, dry cough and subjective fevers. High-resolution CT of the chest revealed diffuse bilateral ground-glass opacities. Infectious and autoimmune causes were excluded. Upadacitinib was discontinued and corticosteroid therapy initiated, resulting in near-complete radiological resolution within 2\u2009months. To our knowledge, this is the first reported case of upadacitinib-induced pneumonitis. Clinicians should remain vigilant for this potential adverse effect as the use of Janus kinase inhibitors expands.<\/jats:p>","DOI":"10.1136\/bcr-2026-273829","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:20:19Z","timestamp":1784730019000},"page":"e273829","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Upadacitinib-induced interstitial pneumonitis"],"prefix":"10.1136","volume":"19","author":[{"given":"Natasha Marcella","family":"Vaselli","sequence":"first","affiliation":[{"name":"Respiratory, Gold Coast University Hospital, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep Kakkadasam","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Department of Digestive Health, Gold Coast University Hospital, Gold Coast Hospital and Health Service, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maninder Pal","family":"Singh","sequence":"additional","affiliation":[{"name":"Respiratory, Gold Coast University Hospital, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2026072207201013000_19.7.e273829.1","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1183\/13993003\/erj.42.Suppl_57.5043","article-title":"Pneumotox - An updated time-saving web resource","volume":"42","author":"Camus","year":"2013","journal-title":"Eur Respir J"},{"key":"2026072207201013000_19.7.e273829.2","article-title":"Drug-induced lung disease: a narrative review","volume":"50","author":"Bridi","year":"2024","journal-title":"J Bras Pneumol"},{"key":"2026072207201013000_19.7.e273829.3","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401206010063"},{"key":"2026072207201013000_19.7.e273829.4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur Respir J"},{"key":"2026072207201013000_19.7.e273829.5","unstructured":"Adverse drug reaction probability scale (naranjo) in drug induced liver injury. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, 2012."},{"key":"2026072207201013000_19.7.e273829.6","article-title":"Navigating Drug-Induced Lung Disease (DILD): A Comprehensive Review on Management and Prevention Strategies","volume":"16","author":"Annareddy","year":"2024","journal-title":"Cureus"},{"key":"2026072207201013000_19.7.e273829.7","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"2026072207201013000_19.7.e273829.8","unstructured":"Hadizamani Y , Messmer F , Bally L , et al . Interstitial Pneumonitis Due to Janus Kinase Inhibitor Baricitinib in a Rheumatic Arthritis Patient. Int J Pul & Res Sci 2020."},{"key":"2026072207201013000_19.7.e273829.9","doi-asserted-by":"crossref","first-page":"120473","DOI":"10.1016\/j.cca.2025.120473","article-title":"Interstitial lung disease biomarkers: a systematic review and meta-analysis","volume":"577","author":"Tzang","year":"2025","journal-title":"Clini Chim Acta"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-273829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:20:21Z","timestamp":1784730021000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-273829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,22]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bcr-2026-273829"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-273829","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}